

## Claims

1. A pharmaceutical composition comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin.
2. A composition according to claim 1 wherein the first specific binding agent comprises a large binding fragment of an antibody.
3. A composition according to claim 2 wherein the large binding fragment of an antibody is a  $F(ab')_2$  or  $F(ab)_2$  fragment.
4. A composition according to claim 1 wherein the first specific binding agent is an antibody which is an IgG or IgT.
5. A composition according to claim 4 wherein the antibody is humanised.
6. A composition according to any one of the preceding claims wherein the second specific binding agent comprises an Fab, Fab', a single chain (sc) antibody or an FV, VH or VK fragment.
7. A composition according to claim 6 wherein the second specific binding agent comprises Fab or Fab' fragment.
8. A composition according to any one of the preceding claims wherein the first and/or second binding agents are derived from polyclonal antibodies.
9. A composition according to any one of claims 1 to 7 wherein the first and/or second binding agents are derived from monoclonal antibodies.

10. A composition according to any one of the preceding claims wherein at least one of the first or second specific binding agents includes a section corresponding to part of the Fc region of an antibody.

5

11. A composition according to any one of the preceding claims wherein the toxin is a Botulinum toxin.

12. A composition according to claim 11 wherein the first and second specific binding agents bind at least one of type A, B, C, D, E, F or G botulinum toxin.

10

13. A composition according to claim 12 wherein the composition comprises sets of first and second specific binding agents each set of specific binding agents binding a different one of botulinum toxins A, B, C, D, E, F or G.

15

14. A composition according to any one of the preceding claims wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 90:10 to 10:90.

20

15. A composition according claim 14 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 70:30 to 30:70.

25

16. A composition according to claim 15 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 60:40 to 40:60.

30

17. A composition according to any one of the preceding claims which further comprises a pharmaceutically acceptable carrier or excipient.

18. A composition according to any one of the preceding claims which is suitable for oral, parenteral, or intranasal

35

administration, or for administration by inhalation or insufflation.

19. A combination of (i) a first specific binding agent  
5 selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin, for use in the treatment of the effects of the toxin.
- 10 20. The use of a combination of (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a  
15 second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin, in the preparation of a medicament for the treatment of the effects of the toxin.
21. A method of preventing the effects of a toxin on a mammal  
20 such as a human, said method comprising administering to a mammal in need thereof, a composition according to any one of claims 1 to 18.
22. A composition substantially as hereinbefore described.  
25